

Haematologica
HAEMATOL/2017/178376
Version 4

A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independent of age, transplant dose, and G-CSF support

Amar Desai, Yongyou Zhang, Youngsoo Park, Dawn M Dawson, Gretchen A Larusch, Lakshmi Kasturi, David Wald, Joseph M Ready, Stanton L Gerson, and Sanford D Markowitz

Disclosures: The authors (A. Desai, Y. Zhang, S.L. Gerson, J.M. Ready, and S.D. Markowitz) hold patents relating to (+)-SW209415 and use of 15-PGDH inhibitors in bone marrow transplantation that have been licensed to Rodeo Therapeutics. Drs. Markowitz, Gerson, and Ready are founders of Rodeo Therapeutics, and Drs. Markowitz, Gerson, Ready and Desai are consultants to Rodeo Therapeutics. Conflicts of interest are managed according to institutional guidelines and oversight by Case Western Reserve University and the University of Texas Southwestern Medical Center. No conflict of interest pertains to any of the remaining authors (Y. Park, D. Dawson, G. Larusch, L. Kasturi, D. Wald).

Contributions: Amar Desai: Conception and Design, Collection of Data, Data Interpretation, Manuscript Writing Yongyou Zhang: Collection of Data Youngsoo Park: Collection of Data Dawn M. Dawson: Collection of Data Gretchen A. Larusch: Collection of Data Lakshmi Kasturi: Collection of Data David Wald: Data Interpretation Joseph M. Ready: Conception and Design, Manuscript Writing Stanton L. Gerson: Conception and Design, Data Interpretation, Manuscript Writing Sanford D. Markowitz: Conception and Design, Data Interpretation, Manuscript Writing, Final Approval of Manuscript